Sjogren Syndrome - Musculoskeletal Manifestations

• Ocular tests. The Schirmer test (filter paper in the lower fornix; abnormal at 5 mm or less of wetting in 5 minutes) and the ocular staining score (lissamine green/fluorescein; abnormal at 5 or more) confirm the keratoconjunctivitis sicca.
• Oral/glandular tests. Unstimulated whole salivary flow (abnormal at 0.1 mL/min or less) and the histological hallmark - a labial (minor) salivary-gland biopsy showing focal lymphocytic sialadenitis with a focus score of at least 1 (one or more foci of 50 or more lymphocytes per 4 mm squared).
• The 2016 ACR/EULAR classification criteria. In a patient with sicca symptoms and no exclusions, a weighted score in which focus score of at least 1 (3 points) and anti-Ro/SSA positive (3 points) are the two heavy items, plus one point each for ocular staining, Schirmer and salivary flow; a total of at least 4 points classifies Sjogren. Note that anti-La/SSB is NOT weighted in the 2016 criteria - only anti-Ro/SSA counts.

View larger

View larger

• Why it happens. Sjogren carries the highest lymphoma risk of the autoimmune connective-tissue diseases (roughly a 5% lifetime risk, about 15-20 times the general population). Chronic B-cell hyperactivation and antigen drive within the lymphocyte-infiltrated glands leads to clonal B-cell expansion, most often an extranodal marginal-zone (MALT) B-cell lymphoma arising in the parotid/salivary gland itself.
• The predictors (high-yield). The high-risk patient is flagged by persistent parotid/salivary-gland enlargement, lymphadenopathy or splenomegaly, palpable purpura / cutaneous vasculitis, low C4 (hypocomplementaemia), cryoglobulinaemia, a serum monoclonal band, and lymphopenia / low CD4 - these should prompt investigation (imaging, gland biopsy).
• The message. New or persistent gland swelling in Sjogren is lymphoma until proven otherwise.

Hydroxychloroquine is the most frequently prescribed immunosuppressant in primary Sjogren syndrome, and it is routinely offered for the arthralgia. The best evidence does not support that practice, and a candidate who quotes hydroxychloroquine as effective without the caveat is quoting habit rather than evidence.

• The trial. JOQUER randomised 120 patients with primary Sjogren syndrome across 15 French university hospitals to hydroxychloroquine 400 mg daily or placebo, double-blind, for 24 weeks.
• The result was flatly negative. The primary endpoint - a 30% or greater reduction in two of three analogue scales for dryness, pain and fatigue - was met by 17.9% (10 of 56) on hydroxychloroquine versus 17.2% (11 of 64) on placebo (odds ratio 1.01, 95% CI 0.37-2.78, P = 0.98). The pain score moved from 5.09 to 4.59 on drug and from 4.92 to 5.08 on placebo: no meaningful separation.
• It was not a compliance failure. All but one patient in the treatment arm had detectable blood levels of the drug, so the null result cannot be explained away by patients not taking it.
• The subgroups you would most expect to respond did not. Hydroxychloroquine had no efficacy in patients with anti-SSA antibodies, with high IgG, or with systemic involvement - precisely the seropositive, systemically active patients in whom it is usually justified.
• What this does and does not mean. The trial measured dryness, pain and fatigue over 24 weeks. It did not test hydroxychloroquine against articular inflammation as a specific endpoint, nor over a longer horizon, and the authors call for studies of longer-term outcomes. Serious adverse events were few and comparable between arms, so the drug is not dangerous - it is simply unproven for symptoms. Prescribing decisions sit with rheumatology, but the honest statement is that no drug has been shown to relieve the symptom burden of primary Sjogren syndrome.

"Very common" and "usually non-erosive" are both defensible, but each needs qualifying.

• The denominator. In a cohort of 133 patients with primary Sjogren syndrome, 115 (86%) had articular involvement - so joint disease is the rule, not an occasional extra. Notably, 91 patients (68% of the whole cohort) already had articular manifestations at the time of the Sjogren diagnosis, with the remainder developing them during the disease course; those whose joints declared later had been diagnosed younger and reported more dryness.
• Which joints. Hands and wrists were most frequently involved, followed by knees, shoulders and ankles
  • so the distribution is not confined to the small joints.
• The important qualification to "non-erosive". Articular manifestations in primary Sjogren syndrome span a spectrum from arthralgia through to EROSIVE ARTHRITIS RESEMBLING RHEUMATOID ARTHRITIS. Most cases are mild and self-limiting, but some patients develop a chronic polyarthritis requiring DMARDs. Teaching "Sjogren arthritis is non-erosive" as an absolute will mislead: it is usually non-erosive, and an erosive course does not exclude the diagnosis or automatically reclassify the patient as rheumatoid.
• Imaging. In that cohort MRI detected more abnormalities than ultrasound, and both were used to quantify the extent of involvement and guide treatment - though this was a retrospective descriptive study with no reference standard, so it reports relative detection, not diagnostic accuracy.